During the past 3 years, the average Dividends Per Share Growth Rate was 26.00% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 18.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Clinuvel Pharmaceuticals was 26.00% per year. The lowest was 7.70% per year. And the median was 21.50% per year.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Clinuvel Pharmaceuticals (ASX:CUV) Dividends per Share Explanation
1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.
Clinuvel Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2025 is calculated as
During the past 13 years, the highest Dividend Payout Ratio of Clinuvel Pharmaceuticals was 0.08. The lowest was 0.05. And the median was 0.07.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
Clinuvel Pharmaceuticals Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
AUD 0.050000
2025-09-04
2025-09-05
2025-09-19
Cash Dividend
annually
AUD:AUD 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Clinuvel Pharmaceuticals's Dividend Yield (%) for Today is calculated as
Current Share Price is A$10.22.
Clinuvel Pharmaceuticals's Dividends per Share for the trailing twelve months (TTM) ended in Today is A$0.05.
During the past 13 years, the highest Dividend Yield of Clinuvel Pharmaceuticals was 0.56%. The lowest was 0.05%. And the median was 0.14%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals Dividends per Share Related Terms
Clinuvel Pharmaceuticals Dividends per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals Dividends per Share Chart
ASX:CUV vs VRTX, REGN, ALNY: Dividends per Share Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Dividend Yield % falls into.
Clinuvel Pharmaceuticals (ASX:CUV) has a Dividends per Share of A$0.05 as of Dec. 2025. Dividends per share represents the per-share amount paid as dividends. View historical data on Clinuvel Pharmaceuticals and its competitors.
Is Clinuvel Pharmaceuticals' Dividends per Share too high?
Clinuvel Pharmaceuticals' current Dividends per Share is A$0.05. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Dividends per Share compare to VRTX and REGN?
Clinuvel Pharmaceuticals' Dividends per Share of A$0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current Dividends per Share is A$0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.76, compared to a current price of A$10.22 — trading 42.5% below its estimated fair value. The current Dividends per Share is A$0.05. Clinuvel Pharmaceuticals' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current Dividends per Share is A$0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of A$10.22 is trading 42.5% below its estimated GF Value™ of A$17.76.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ASX:CUV:
Dividends per Share: A$0.05
GF Value™: A$17.76 vs. price of A$10.22 (42.5% below fair value)
No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
85GF Score
Get the complete analysis for ASX:CUV
Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CUV has been successfully added to your 
